EPAS1 and neoplasm: While neither of these compounds has been used in patients with PHEO/PGL, the tumor-suppressing effects of HIF-2α inhibitors in HIF-driven tumors such as ccRCCs are promising and indicate that they could have potential therapeutic options for patients with cluster I PHEO/PGL.